Artificial cytokine storm combined with hyperthermia induces significant anti-tumor effect in mice inoculated with Lewis lung carcinoma and B16 melanoma cells

References

• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909–915
   PubMed Web of Science ®Google Scholar
• Chouaib S, Asselin-Paturel C, Mami-Chouaib F, Caignard A, Blay JY. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today 1997; 18: 493–497
   PubMedGoogle Scholar
• Song CW. Effect of local hyperthermia on blood flow and microenvironment: A review. Cancer Res 1984; 44: 4721s–4730s
   PubMed Web of Science ®Google Scholar
• Geehan DM, Fabian DF, Lefor AT. Combined local hyperthermia and immunotherapy treatment of an experimental subcutaneous murine melanoma. J Surg Oncol 1995; 59: 35–39
   PubMedGoogle Scholar
• Ito A, Tanaka K, Kondo K, Shinkai M, Honda H, Matsumoto K, Saida T, Kobayashi T. Tumor regression by combined immunotherapy and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma. Cancer Sci 2003; 94: 308–313
   PubMed Web of Science ®Google Scholar
• Lin JC, Park HJ, Song CW. Combined treatment of IL-1α and TNF-α potentiates the antitumour effect of hyperthermia. Int J Hyperthermia 1996; 12: 335–344
   PubMed Web of Science ®Google Scholar
• Nakayama J, Kokuba H, Kobayashi J, Yoshida Y, Hori Y. Experimental approaches for the treatment of murine B16 melanomas of various sizes. II: Injection of ethanol with combinations of β-interferon and microwaval hyperthermia for B16 melanomas with a size of greater than 10 mm in diameter. J Dermatol Sci 1997; 15: 82–88
   PubMed Web of Science ®Google Scholar
• Murakami M, Sakamoto A, Bender J, Kappler J, Marrack P. CD25+CD4+ T cells contribute to the control of memory CD8+ T cells. Proc Natl Acad Sci USA 2002; 99: 8832–8837
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Interleukin-12: A cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994; 84: 4008–4027
   PubMed Web of Science ®Google Scholar
• Croft M, Carter L, Swain SL, Dutton RW. Generation of polarized antigen-specific CD8 effector populations: Reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med 1994; 180: 1715–1728
   PubMed Web of Science ®Google Scholar
• Halloran PF, Urmson J, van der Meide PH, Autenried P. Regulation of MHC expression in vivo. II. IFN-α/β inducers and recombinant IFN-α modulate MHC antigen expression in mouse tissues. J Immunol 1989; 142: 4241–4247
   PubMed Web of Science ®Google Scholar
• Biron CA. Cytokines in the generation of immune responses to, and resolution of, virus infection. Curr Opin Immunol 1994; 6: 530–538
   PubMed Web of Science ®Google Scholar
• Krakauer T, Oppenheim JJ. IL-1 and tumor necrosis factor-α each up-regulate both the expression of IFN-γ receptors and enhance IFN-γ-induced HLA-DR expression on human monocytes and a human monocytic cell line (THP-1). J Immunol 1993; 150: 1205–1211
   PubMed Web of Science ®Google Scholar
• Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, Grewal N, Spiess PJ, Antony PA, Palmer DC, Tagaya Y, Rosenberg SA, Waldmann TA, Restifo NP. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci USA 2004; 101: 1969–1974
   PubMed Web of Science ®Google Scholar
• Osaki T, Peron J-M, Cai Q, Okamura H, Robbins PD, Kurimoto M, Lotze MT, Tahara H. IFN-γ-inducing factor/IL-18 administration mediates IFN-γ- and IL-12-independent antitumor effects. J Immunol 1998; 160: 1742–1749
   PubMed Web of Science ®Google Scholar
• Wood DD, Bayne EK, Goldring MB, Gowen M, Hamerman D, Humes JL, Ihrie EJ, Lipsky PE, Staruch MJ. The four biochemically distinct species of human interleukin 1 all exhibit similar biologic activities. J Immunol 1985; 134: 895–903
   PubMed Web of Science ®Google Scholar
• Storozynsky E, Woodward JG, Frelinger JG, Lord EM. Interleukin-3 and granulocyte-macrophage colony-stimulating factor enhance the generation and function of dendritic cells. Immunology 1999; 97: 138–149
   PubMedGoogle Scholar
• Brunda MJ, Wright RB, Luistro L, Harbison ML, Anderson TD, Mclntyre KW. Enhanced antitumor efficacy in mice by combination treatment with interleukin-1α and interferon-α. J Immunother Emphasis Tumor Immunol 1994; 15: 233–241
   PubMedGoogle Scholar
• Harada M, Tamada K, Abe K, Li T, Onoe Y, Tada H, Takenoyama M, Yasumoto K, Kimura G, Nomoto K. Systemic administration of interleukin-12 can restore the anti-tumor potential of B16 melanoma-draining lymph node cells impaired at a late tumor-bearing state. Int J Cancer 1998; 75: 400–405
   PubMed Web of Science ®Google Scholar
• Peng BG, Liu SQ, Kuang M, He Q, Totsuka S, Huang L, Huang J, Lu MD, Liang LJ, Leong KW, et al. Autologous fixed tumor vaccine: a formulation with cytokine-microparticles for protective immunity against recurrence of human hepatocellular carcinoma. Jpn J Cancer Res 2002; 93: 363–368
   PubMedGoogle Scholar
• Metcalf D, Begley CG, Johnson GR, Nicola NA, Lopez AF, Williamson DJ. Effects of purified bacterially synthesized murine multi-CSF (IL-3) on hematopoiesis in normal adult mice. Blood 1986; 68: 46–57
   PubMed Web of Science ®Google Scholar
• Abe T, Sugaya H, Ishida K, Khan WI, Tasdemir I, Yoshimura K. Intestinal protection against Strongyloides ratti and mastocytosis induced by administration of interleukin-3 in mice. Immunology 1993; 80: 116–121
   PubMedGoogle Scholar
• Lotem J, Sachs L. In vivo control of differentiation of myeloid leukemic cells by recombinant granulocyte-macrophage colony-stimulating factor and interleukin 3. Blood 1988; 71: 375–382
   PubMed Web of Science ®Google Scholar
• Ito A, Fujioka M, Tanaka K, Kobayashi T, Honda H. Screening of cytokines to enhance vaccine effects of heat shock protein 70-rich tumor cell lysate. J Biosci Bioeng 2005; 100: 36–42
   PubMed Web of Science ®Google Scholar
• Gallagher G, Zaloom Y. Peritumoural IL-4 treatment induces systemic inhibition of tumour growth in experimental melanoma. Anticancer Res 1992; 12: 1019–1024
   PubMedGoogle Scholar
• Redmond HP, Schuchter L, Bartlett D, Kelly CJ, Shou J, Leon P, Daly JM. Anti-neoplastic effects of interleukin-4. J Surg Res 1992; 52: 406–411
   PubMedGoogle Scholar
• Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, Gately MK. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993; 178: 1223–1230
   PubMed Web of Science ®Google Scholar
• Hashimoto W, Osaki T, Okamura H, Robbins PD, Kurimoto M, Nagata S, Lotze MT, Tahara H. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. J Immunol 1999; 163: 583–589
   PubMed Web of Science ®Google Scholar
• Lasek W, Golab J, MaSlinski W, Switaj T, Balkowiec EZ, Stoklosa T, Giermasz A, Malejczyk M, Jakobisiak M. Subtherapeutic doses of interleukin-15 augment the antitumor effect of interleukin-12 in a B16F10 melanoma model in mice. Eur Cytokine Netw 1999; 10: 345–356
   PubMed Web of Science ®Google Scholar
• Prell RA, Li B, Lin JM, VanRoey M, Jooss K. Administration of IFN-α enhances the efficacy of a granulocyte macrophage colony stimulating factor-secreting tumor cell vaccine. Cancer Res 2005; 65: 2449–2456
   PubMed Web of Science ®Google Scholar
• De Maeyer-Guignard J, Lauret E, Eusebe L, De Maeyer E. Accelerated tumor development interferon-treated B6.C-Hyal-1 a mice. Proc Natl Acad Sci USA 1993; 90: 5708–5712
   PubMedGoogle Scholar
• Saiki I, Sato K, Yoo YC, Murata J, Yoneda J, Kiso M, Hasegawa A, Azuma I. Inhibition of tumor-induced angiogenesis by the administration of recombinant interferon-γ followed by a synthetic lipid-A subunit analogue (GLA-60). Int J Cancer 1992; 51: 641–645
   PubMedGoogle Scholar
• Tsutsumi Y, Tsunoda S, Kaneda Y, Kamada H, Kihira T, Nakagawa S, Yamamoto Y, Horisawa Y, Mayumi T. In vivo anti-tumor efficacy of polyethylene glycol-modified tumor necrosis factor-alpha against tumor necrosis factor-α tumors. Jpn J Cancer Res 1996; 87: 1078–1085
   PubMedGoogle Scholar
• Lasek W, Feleszko W, Golab J, Stoklosa T, Marczak M, Dabrowska A, Malejczyk M, Jakobisiak M. Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor α in mice. Cancer Immunol Immunother 1997; 45: 100–108
   PubMed Web of Science ®Google Scholar
• Charak BS, Agah R, Mazumder A. Granulocyte-macrophage colony-stimulating factor-induced antibody-dependent cellular cytotoxicity in bone marrow macrophages: application in bone marrow transplantation. Blood 1993; 81: 3474–3479
   PubMed Web of Science ®Google Scholar
• Fleischmann WR, Jr, Fleischmann CM. Enhancement of MuIFN-γ antitumor effects by hyperthermia: sequence dependence and time dependence of hyperthermia. J Biol Regul Homeost Agents 1994; 8: 101–107
   PubMedGoogle Scholar
• Novick D, Cohen B, Rubinstein M. The human interferon α/β Receptor: Characterization and molecular cloning. Cell 1994; 77: 391–400
   PubMed Web of Science ®Google Scholar
• McCune CS, Marquis DM. Interleukin 1 as an adjuvant for active specific immunotherapy in a murine tumor model. Cancer Res 1990; 50: 1212–1215
   Google Scholar
• Arca MJ, Krauss JC, Strome SE, Cameron MJ, Chang AE. Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes. Cancer Immunol Immunother 1996; 42: 237–245
   PubMed Web of Science ®Google Scholar
• Rashid RM, Achille NJ, Lee JM, Lathers DM, Young MR. Decreased T-cell proliferation and skewed immune responses in LLC-bearing mice. J Environ Pathol Toxicol Oncol 2005; 24: 175–192
   PubMed Web of Science ®Google Scholar
• Utsumi K, Takai Y, Tada T, Ohzeki S, Fujiwara H, Hamaoka T. Enhanced production of IL-6 in tumor-bearing mice and determination of cells responsible for its augmented production. J Immunol 1990; 145: 397–403
   PubMed Web of Science ®Google Scholar
• Ito A, Matejuk A, Hopke C, Drought H, Dwyer J, Zamora A, Subramanian S, Vandenbark A, Offner H. Transfer of severe experimental autoimmune encephalomyelitis by IL-12- and IL-18-potentiated T cells is estrogen sensitive. J Immunol 2003; 170: 4802–4809
   PubMed Web of Science ®Google Scholar
• O’Regan B, Hirshberg C. Spontaneous remission. An annotated bibliography. Infection Related Remission, GL Rohdenburg, HC Nauts, WE Swift, BL Coley, GA Fowler, FH Bogatko, L Pelner, J Fauvet, J Campagne, A Chavy, et al. Institute of Noetic Sciences, Sausalito, CA 1993; 577–646
   Google Scholar
• Lauerova L, Dusek L, Simickova M, Kocak I, Vagundova M, Zaloudik J, Kovarik J. Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response. Neoplasma 2002; 49: 159–166
   PubMed Web of Science ®Google Scholar
• Hendel-Fernandez ME, Cheng X, Herbert LM, Lopez DM. Down-regulation of IL-12, not a shift from a T helper-1 to a T helper-2 phenotype, is responsible for impaired IFN-γ production in mammary tumor-bearing mice. J Immunol 1997; 158: 280–286
   PubMedGoogle Scholar
• Dillman RO, Shea WM, Tai DF, Mahdavi K, Barth NM, Kharkar BR, Poor MM, Church CK, DePriest C. Interferon-α2a and 13-cis-retinoic acid with radiation treatment for high-grade glioma. Neuro-oncol 2001; 3: 35–41
   PubMed Web of Science ®Google Scholar
• Goker E, Sanli UA, Yuzer Y, Uslu R, Karabulut B, Memis A, Coker A, Mentes A. Bioembolisation for unresectable hepatocellular carcinoma: preliminary results of a translational research study. J Exp Clin Cancer Res 2004; 23: 403–409
   PubMedGoogle Scholar
• Boehm T, Folkman J, Browder T, O’Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404–407
   PubMed Web of Science ®Google Scholar
• Savage DG, Antman KH. Imatinib mesylate-a new oral targeted therapy. N Eng J Med 2002; 346: 683–693
   PubMed Web of Science ®Google Scholar
• Robins HI, d’Oleire F, Kutz M, Bird A, Schmitt-Tiggelaar CL, Cohen JD, Spriggs DR. Cytotoxic interactions of tumor necrosis factor, melphalan and 41.8°C hyperthermia. Cancer Lett 1995; 89: 55–62
   PubMedGoogle Scholar